相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects
Asal Jalal Abadi et al.
PHYTOTHERAPY RESEARCH (2022)
The prevalence of frailty among breast cancer patients: a systematic review and meta-analysis
Shurui Wang et al.
SUPPORTIVE CARE IN CANCER (2022)
Nanomedicine Strategies to Circumvent Intratumor Extracellular Matrix Barriers for Cancer Therapy
Xiaoxuan Xu et al.
ADVANCED HEALTHCARE MATERIALS (2022)
Coping Strategies in Elderly Colorectal Cancer Patients
Keyla Vargas-Roman et al.
CANCERS (2022)
A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology
Daniel Erku et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2021)
Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor
Kelly M. Hotchkiss et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Is there scope for better individualisation of anthracycline cancer chemotherapy?
Benedetta C. Sallustio et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Recent advances in lipid-engineered multifunctional nanophytomedicines for cancer targeting
Mayank Handa et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study
In Gyu Hwang et al.
CANCERS (2021)
Clinical and therapeutic features and prognostic factors of metastatic colorectal cancer over age 80: a retrospective study
Hiroyuki Hisada et al.
BMC GASTROENTEROLOGY (2021)
Kidney injury and disease in patients with haematological malignancies
Frank Bridoux et al.
NATURE REVIEWS NEPHROLOGY (2021)
Angiogenesis as a hallmark of solid tumors-clinical perspectives
Jamal Majidpoor et al.
CELLULAR ONCOLOGY (2021)
Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities
Rabin Neupane et al.
PHARMACEUTICS (2021)
Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italian Oncologia Medica (AIOM)/Associazione Medici Diabetology (AMD)/Societa Italiana Endocrinologia (SIE)/Societa Italiana Farmacologia (SIF) multidisplinary consensus position paper
N. Silvestris et al.
ESMO OPEN (2021)
The Influence of Adjuvant Chemotherapy Dose Intensity on Five-Year Outcomes in Resected Colon Cancer: A Single Centre Retrospective Analysis
Suganija Lakkunarajah et al.
CURRENT ONCOLOGY (2021)
Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020
Caixia Dong et al.
CHINESE JOURNAL OF CANCER RESEARCH (2021)
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
Yojiro Hashiguchi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Chiara Cremolini et al.
LANCET ONCOLOGY (2020)
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
Carlotta Antoniotti et al.
BMC CANCER (2020)
Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies
Claudia Pellacani et al.
ADVANCES IN MEDICAL SCIENCES (2020)
Cost-effectiveness of Capecitabine plus Irinotecan Versus Leucovorin plus Fluorouracil plus Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China
Qiuji Wu et al.
CLINICAL THERAPEUTICS (2020)
Geriatric management of older patients with multimorbidity
Taro Kojima et al.
GERIATRICS & GERONTOLOGY INTERNATIONAL (2020)
Clinical pharmacology of oncology agents in older adults: A comprehensive review of how chronologic and functional age can influence treatment-related effects
Ginah Nightingale et al.
JOURNAL OF GERIATRIC ONCOLOGY (2019)
The rationale of dose-response curves in selecting cancer drug dosing
Jennifer H. Martin et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.
Chiara Cremolini et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies
F. Marmorino et al.
ANNALS OF ONCOLOGY (2019)
OPTIMIZING CHEMOTHERAPY FOR FRAIL AND/OR ELDERLY PATIENTS WITH ADVANCED GASTROESOPHAGEAL CANCER (AGOAC): THE GO2 PHASE III TRIAL
D.E. Swinson et al.
Journal of Geriatric Oncology (2019)
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)
Herbert Hurwitz et al.
ONCOLOGIST (2019)
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumabas First-line Chemotherapy in Metastatic Colorectal Cancer
Aparna R. Parikh et al.
CLINICAL CANCER RESEARCH (2019)
Burden of colorectal cancer in China, 1990-2017: Findings from the Global Burden of Disease Study 2017
Jie Yin et al.
CHINESE JOURNAL OF CANCER RESEARCH (2019)
Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer
Roberto Petrioli et al.
CLINICAL COLORECTAL CANCER (2018)
Promising New Agents for Colorectal Cancer
Satya Das et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
Rui-Hua Xu et al.
LANCET ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Causes of death among cancer patients
N. G. Zaorsky et al.
ANNALS OF ONCOLOGY (2017)
Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice
S. J. Schraa et al.
EUROPEAN JOURNAL OF CANCER (2017)
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer
Ji-Won Kim et al.
ONCOLOGIST (2017)
Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6-treated patients
Yang Chen et al.
BMC CANCER (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
Chiara Cremolini et al.
LANCET ONCOLOGY (2015)
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial
T. Gruenberger et al.
ANNALS OF ONCOLOGY (2015)
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
Tomas Buchler et al.
BMC CANCER (2014)
Review of therapeutic drug monitoring of anticancer drugs part 1-Cytotoxics
Angelo Paci et al.
EUROPEAN JOURNAL OF CANCER (2014)
A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes
Ryouichi Tsunedomi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Fotios Loupakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
FOLFOX 4 Combined with Herbal Medicine for Advanced Colorectal Cancer: A Systematic Review
Menghua Chen et al.
PHYTOTHERAPY RESEARCH (2014)
Management of locally advanced and metastatic colon cancer in elderly patients
Peter C. Kurniali et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Antiangiogehic Drugs for Colorectal Cancer: Exploring New Possibilities
Renata Ferrarotto et al.
CLINICAL COLORECTAL CANCER (2013)
Prevalence of Multiple Chronic Conditions Among US Adults: Estimates From the National Health Interview Survey, 2010
Brian W. Ward et al.
PREVENTING CHRONIC DISEASE (2013)
Neoadjuvant and adjuvant therapy in relation to surgery for colorectal liver metastases
Antoine Brouquet et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2012)
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer
E. Marcuello et al.
BRITISH JOURNAL OF CANCER (2011)
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
J. Cassidy et al.
BRITISH JOURNAL OF CANCER (2011)
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
Michel Ducreux et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma
Tomohiro Nishi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2011)
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
Matthew T. Seymour et al.
LANCET (2011)
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)
Kei Muro et al.
LANCET ONCOLOGY (2010)
The Four-Herb Chinese Medicine PHY906 Reduces Chemotherapy-Induced Gastrointestinal Toxicity
Wing Lam et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
Gary H. Lyman
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer.: EORTC study 40015
C.-H. Koehne et al.
ANNALS OF ONCOLOGY (2008)
Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials
Hendrik-Tobias Arkenau et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer:: Combined analysis of 2,691 patients in randomized controlled trials
Gunnar Folprecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
Jim Cassidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Potential regional differences for the tolerability profiles of fluoropyrimidines
Daniel G. Haller et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
Charles S. Fuchs et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer
J. Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience
Toshio Shimizu et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
Alfredo Falcone et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):: a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
J Souglakos et al.
BRITISH JOURNAL OF CANCER (2006)
Perspectives in the treatment of colorectal cancer
H Ozer et al.
SEMINARS IN ONCOLOGY (2004)
分享论文
